March 9 (Reuters) - GSK said on Monday it will receive up to $690 million from Italian pharmaceutical company Alfasigma for ...

FDA worked with GSK to update Wellcovorin labelling for safe, effective use in adult and paediatric CFD-FOLR1 patients.

After nearly nine years as GSK’s CEO, Emma Walmsley exited on a high note as her total compensation for 2025 surged nearly 50% to 15.7 million pounds sterling ($21 million). | After nearly nine years ...

Under the deal, Alfasigma will gain rights to develop, manufacture and commercialize linerixibat.

GSK plc GSK signed a license agreement with Italy-based Alfasigma. Per the terms of the agreement, Alfasigma has acquired exclusive global rights from GSK to develop and market linerixibat, an ...

Bulk of 2025 renumeration came from share bonuses as drug company’s now former CEO benefitted from stock rise ...

If you are wondering whether GSK is still attractively priced after its recent run, you are not alone and this article is for ...

"After you take some well-deserved time off … let's do it again!" the chair of RAPT Therapeutics' board tells co-founder-CEO ...

Ten small and medium-sized charities have been named as winners of the 2026 GSK IMPACT Awards for their exceptional work improving health and wellbeing.

The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair.

It posted double-digit percentage growth in its immunology and inflammation, oncology and HIV portfolios for 2025, with sales ...

Months after promising help for “hundreds of thousands of kids,” the FDA approved the decades-old medicine for a disease documented in less than 50 people.